← Eichor
Study identifier: NCT04121468 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis

Condition: Multiple Sclerosis (MS)  ·  Sponsor: The Hospital for Sick Children

PhasePhase 1/Phase 2
Planned participants20
Who can joinAll sexes, 10 Years to 25 Years
Healthy volunteersNo

About this study

A randomized multiple baseline feasibility trial where participants will start taking metformin at one of 3 randomly determined points (3-months, 6-months or 9 months) during the 12-month trial. All subjects will be on a daily dose of metformin for a minimum of 3 months and a maximum of 9 months.

This description comes directly from the study's public registry record.

Talk to the study team

E. Ann Yeh, MA, MD, FRCPC, Dip ABPN  ·  416-813-7353  ·  ann.yeh@sickkids.ca

Brenna Wong  ·  416-813-7654  ·  brenna.wong@sickkids.ca

Always discuss trial participation with your own doctor first.

Locations (1)

The Hospital for Sick ChildrenToronto, Ontario, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04121468